The European Patent Office (EPO) has decided that the European patent on mutations in breast and ovarian cancer susceptibility (EP 705903) is to be maintained in amended form.
Related Articles
Cover Story
Pat Price: asking the right questions
Spotlight on
How much is too much? Will someone please take charge of finding answers?
Drug Watch